March 26, 2020 / 1:05 PM / 7 days ago

BRIEF-Calmark Comments On The Effects From COVID-19

March 26 (Reuters) - Calmark Sweden AB:

* CALMARK COMMENTS ON THE EFFECTS FROM COVID-19 AND ANNOUNCES UPDATED TIMETABLE FOR CLINICAL TRIAL AT SÖDERSJUKHUSET

* UP UNTIL NOW, CALMARK’S DEVELOPMENT PROJECT HAS NOT BEEN NEGATIVELY IMPACTED BY COVID-19 OUTBREAK

* WORK IS PROGRESSING AT BEST POSSIBLE PACE

* IT IS DIFFICULT TO ASSESS TODAY HOW REPRIORITIZATIONS AND REORGANIZATIONS WILL AFFECT COMPANY AND STUDY

* AT PRESENT, IT IS DIFFICULT TO ASSESS CONSEQUENCES OF COVID-19 FOR COMPANY, BOTH WITH REGARD TO OUTBREAK ITSELF AND DECISIONS THAT FOLLOW IN ITS WAKE

* CALMARK’S LIQUIDITY IS ABUNDANT FOR TIME BEING THANKS TO DIRECTED RIGHTS ISSUE WHICH WAS CARRIED OUT IN DECEMBER 2019

* TEMPORARY MODIFICATIONS MADE TO COMPANY’S SALES PROCESS MAY AFFECT PACE OF MARKET LAUNCH Source text for Eikon: Further company coverage: (Gdansk Newsroom)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below